< Back to previous page
Researcher
Gert De Meerleer
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Radiotherapy (Division)
Member
From1 Oct 2016 → Today
Projects
1 - 4 of 4
- Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE)From24 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metastasis-directed therapy in castration-refractory prostate cancer: MEDCAREFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Novel insights in the definition and treatment of high risk and oligometastatic prostate cancerFrom1 Oct 2018 → 18 Nov 2022Funding: FWO fellowships
- Traveling the prostate cancer timeline in chase of treatment paradigms Can we cure the incurable?From1 Aug 2017 → 1 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 117
- Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review(2023)
Authors: Gert De Meerleer
Pages: 65 - 85 - ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer(2023)
Authors: Gert De Meerleer
- ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer(2023)
Authors: Gaëtan Devos, Marcella Baldewijns, Karolien Goffin, Annouschka Laenen, Gert De Meerleer, Charlien Berghen, Frank Claessens, Hendrik Van Poppel, Wouter Everaerts, Steven Joniau
- Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial(2023)
Authors: Charlien Berghen, Gert De Meerleer
Pages: 317 - 324 - Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy(2023)
Authors: Gaëtan Devos, Charlien Berghen, Wouter Everaerts, Gert De Meerleer, Steven Joniau
Pages: 92 - 99 - Post-prostatectomy radiotherapy: does late toxicity lead the game?(2022)
Authors: Gert De Meerleer
Pages: 705 - 707 - Novel strategies in the management of high-risk and oligometastatic prostate cancer(2022)
Authors: Gaëtan Devos, Steven Joniau, Wouter Everaerts, Gert De Meerleer
- Editorial Comment.(2022)
Authors: Gert De Meerleer
Pages: 1054 - 1055 - Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy Comment(2022)
Authors: Gert De Meerleer
Pages: 1054 - 1055 - High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer(2022)
Authors: Maarten Lambrecht, Karin Haustermans, Gert De Meerleer